Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

By Qiurong Ruan, Kun Yang, Wenxia Wang, Lingyu Jiang, Jianxin Song. Intensive Care Medicine, 2020

4,618 citations recorded by the source corpus.

Dear Editor, The rapid emergence of COVID-19 in Wuhan city, Hubei Province, China, has resulted in thousands of deaths [1]. Many infected patients, however, presented mild flu-like symptoms and quickly recover [2]. To effectively prioritize resources for patients with the highest risk, we identified clinical predictors of mild and severe patient outcomes. Using the database of Jin Yin-tan Hospital and Tongji Hospital, we conducted a retrospective multicenter study of 68 death cases (68/150, 45%) and 82 discharged cases (82/150, 55%) with laboratory-confirmed infection of SARS-CoV-2. Patients met the discharge criteria if they had no fever for at least 3 days, significantly improved respiratory function, and had negative SARS-CoV-2 laboratory test results twice in succession. Case data included demographics, clinical characteristics, laboratory results, treatment options and outcomes. For statistical analysis, we represented continuous measurements as means (SDs) or as medians (IQRs) which compared with Student’s t test or the Mann–Whitney–Wilcoxon test. Categorical variables were expressed as numbers (%) and compared by the χ2 test or Fisher’s exact test. The distribution of the enrolled patients’ age is shown in Fig. 1a. There was a significant difference in age between the death group and the discharge group (p < 0.001) but no difference in the sex ratio (p = 0.43). A total of 63% (43/68) of patients in the death group and 41% (34/82) in the discharge group had underlying diseases (p = 0.0069). It should be noted that patients with cardiovascular diseases have a significantly increased risk of death when they are infected with SARS-CoV-2 (p < 0.001). A total of 16% (11/68) of the patients in the death group had secondary infections, and 1% (1/82) of the patients in the discharge group had secondary infections (p = 0.0018). Laboratory results showed that there were significant differences in white blood cell counts, absolute values of lymphocytes, platelets, albumin, total bilirubin, blood urea nitrogen, blood creatinine, myoglobin, cardiac troponin, C-reactive protein (CRP) and interleukin-6 (IL-6) between the two groups (Fig. 1b and Supplementary Table 1). The survival times of the enrolled patients in the death group were analyzed. The distribution of survival time from disease onset to death showed two peaks, with the first one at approximately 14 days (22 cases) and the second one at approximately 22 days (17 cases) (Fig. 1c). An analysis of the cause of death was performed. Among the 68 fatal cases, 36 patients (53%) died of respiratory failure, five patients (7%) with myocardial damage died of circulatory failure, 22 patients (33%) died of both, and five remaining died of an unknown cause (Fig. 1d). Based on the analysis of the clinical data, we confirmed that some patients died of fulminant myocarditis. In this study, we first reported that the infection of SARS-CoV-2 may cause fulminant myocarditis. Given that fulminant myocarditis is characterized by a rapid progress and a severe state of illness [3], our results should alert physicians to pay attention not only to the symptoms of respiratory dysfunction but also the symptoms of cardiac injury. *Correspondence: songsingsjx@sina.com 4 Department of Infectious Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan 430030, Hubei, China Full author information is available at the end of the article

Subfields: Infectious Diseases, Neurology, Oncology

View Paper: https://www.semanticscholar.org/paper/45277221c69d768ca10baf87da80c024ad6bdf88

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

In Neurology

In Oncology

Citations in the corpus

The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China (2020, background): “reported 19 (19%) patients were treated with glucocorticoids for 3-15 days (median 5 [3] [4] [5] [6] [7] ), and methylprednisolone (1-2 mg/kg per day) are recommended for patients with ARDS, for as short a duration of treatment as possible [25] .”
The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease (2020, background): “Although inflammation is more lung centered, than multi-organ, the argument for IL-6 involvement in COVID-19 related MAS comes from biochemical parameters changes including ferritin and the preliminary open reports of anti-IL6R efficacy [28,50].”
SARS-CoV-2 infection: The role of cytokines in COVID-19 disease (2020, neutral): “[87] Retrospective study To establish predictors of mortality in patients infected with”
Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia – A systematic review, meta-analysis, and meta-regression (2020, neutral): “[3, 8, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] 9, [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [10] [11] [12] [13] [14] [15] [16] There were a total of 6452 patients from 30 studies.”
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. (2020, background): “Time from symptoms onset to randomization, median (IQR), d 62 10 (7-13) 66 10 (8-13)”
Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis (2020, background): “2020 [7] Retrospective Wuhan, China 150 102/150 (68%) 67 non-survivor and 50 survivor (median) 8.”
COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options (2020, background): “In addition, the cytokine storm can contribute to development of endothelial dysfunction through well-characterized mechanisms.62–65 COVID-19 and coagulation abnormalities Features of disseminated intravascular coagulation (DIC) and pulmonary embolism, characterized by increased D-dimer levels and f”
Individuals with obesity and COVID‐19: A global perspective on the epidemiology and biological relationships (2020, background): “related mortality among COVID-19 patients, which was predicted by elevated serum IL-6.(143) Similarly, elevated IL-6 is a hallmark of severe SARS-CoV,(146) MERS-CoV(147) and pandemic H1N1 influenza A viral infections.”
Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study (2020, background): “Higher levels of IL-6, which have been observed among COVID-19 patients with more severe clinical illness, 17, 18 were also associated with in-hospital mortality.”